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THERAPEUTIC EQUIVALENCE
STUDY OF TWO FORMULATIONS
(INNOVATOR V. GENERIC) OF
BECLOMETHASONE
DIPROPIONATE IN ADULT
ASTHMATIC PATIENTS
Haylene Nell, Charlene M Louw, Helen Cyster, Zelda
Williams, Philip G Bardin, James R Joubert
Objective. To study the thera~ticequivalence of two
formulations (innovator v. generic) of beelomethasone
dipropionate (BDP) 400 pg twice daily administered per
metered dose inhaler (MOn, in adults with moderate to
severe asthma.
Methods. A double-blind randomised parallel-group trial was
performed with a 2-week run-in and an 8-week treabnent
period. Thirty-six symptomatic adult asthmatics on a mean
daily dose df 750 pg inhaled corticosteroids during run-in, a
mean forced expiratory volume in 1 second (FEY1) of 70%
predicted normal and a mean histamine concentration
provoking a 20% reduction in FEYl (histamine PC~ of 0.11 mg/l
were randomised to one of the two treabnent groups.
Primary variables were morning peak expiratory flow
(mPEF), FEYl and histamine PC2l)- Secondary variables were
~-agonistuse, symptom score and nocturnal awakening.
The Schuirmann two one-sided tests procedure was used for
the statistical analysis. Ninety-five per cent confidence
intervals (Os) were calculated for the differences in means.
Results. The mean differences end of treabnent to baseline for
the two formulations (Becotide and Beclate) respectively
were: mPEF 5.61/min (a -16.4 - 27.6) and -22.31/min
(a -35.6 - -9); FEY1 -2.90/0 (a -11 - 5.2) and 0.2% (a -4.8 -
5.2); Histamine PC20 -{I.04 mg/ml (a -{I.15 - 0.06) and
0.02 mg/ml (a -{I.37 - 0.4). Changes in clinical variables
were not conclusive. The mean differences with Os for
primary variables were contained within the limits set for
equivalence. The sample size was sufficient to differentiate
the groups for mPEF, but this was not of clinical significance.
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Conclusion. After 8 weeks of treabnent the two formulations
of BDP, delivered by MDI through a large-volume spacer,
were therapeutically equivalent in moderate-to-severe
asthmatic adults.
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An improved understanding of the pathophysiology of asthma
has strengthened the case for intervention with inhaled
glucocorticosteroids. Allergic inflammation underlies ihe
clinical symptoms in even the mildest forms of asthmaY
Inhaled glucocorticosteroids are ihe proven anti-inflammatory
therapy in chronic asthma because of their remarkable efficacy
and good safety profile.'-6 This therapy is now recommended
for use in ihe early stages of asthma, with the possibility of
preventing structural changes and thereby reducing asthma
mortality and morbidityP Inhaled glucocorticosteroids,
delivered by metered dose inhaler (MDI), should preferably be
administered through a large-volume spacer to minimise
oropharyngeal drug deposition and thereby systemic
absorption and local side-effects.5"".9
There is an increasing tendency to use generic formulations
or interchangeable multi-source products with an anticipated
reduction in health costs.,o-l2 Well-established guidelines are
available for judging equivalence between oral formulations,
but determination of bie-equivalence for inhaled products
remains problematic.n.•, Equivalence for oral formulations is
usually determined by clinical studies demonstrating
comparable bie-availability of generic compounds with original
medications." An exception has been made in the case of
inhaled medications because ')f a lack of standardised or
generally accepted meihods of demonstrating equivalence.
The surrogate criterion usually employed is in vitro
equivalence, without necessarily invoking comparable clinical
efficacy.n.13 This departure from standard practice has been a
subject of debate." According to a consensus statement by the
British Association for Lung Research in 1994, ihe endpoint for
any determination of equivalence of inhaled medications
should be iherapeutic equivalenceY
The objective of this study was to determine the therapeutic
equivalence of an innovator versus a generic formulation of
inhaled beclomethasone dipropionate (BDP) in adults with
moderate asthrP.a. Few studies comparing generic inhaled
formulations and the original products have been reported.l5
PATIENTS AND METHODS
Patients
Thirty-six non-smoking moderate-to-severe asthmatics
diagnosed according to American Thoracic Society criteria,
were recruited." Patient characteristics are listed in Table 1.
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Table I. Baseline characteristics of study patients, mean (SEM)
FEV]%
Sex Symptom of predicted Histamine
Age M/F Atopy score normal Pew
Total group 38.6 12/24 35 1.6 70 N :271.6
(N:36) (1.9) (0.2) (2.0) (0.2)
Group 1 38.4 6/12 18 1.3 73.6 N: 151.3
(N: 18) (2.7) (0.2) (3.0) (0.2)
Group 2 38.8 6/12 17 1.79 66.6 N: 121.79
(N: 18) (2.9) (0.2) (2.5) (0.2)
SEM ; standazd error of mean.
Table lL Stable. dose of inhaled glucocorticosteroids for 8 weeks
before study entry
changes from baseline to end of treatment in: (z) ~2-agonist use;
(ii) symptom score (0: no symptoms, 1 =mild symptoms, 2 =
moderate symptoms, 3 = severe symptoms); and (iiz) nocturnal
awakening, recorded daily in patient diaries. Safety variables
were incidents of exacerbation and other reported adverse
events.
All eligible patients were entered in a 2-week run-in period
during which baseline data were collected. A diary and mini-
Wright peak flow meter (Clement Clarke Int., London, UK)
were supplied to all patients at the first visit. Patients were
asked to record twice-daily peak flow measurements, graded
symptom score, ~2-agonist use and nocturnal awakening.
SalbutamollOO pg/actuation was dispensed to patients at the
first and subsequent visits to standardise ~Tagonistuse.
Symptomatic patients complying with the randomisation
criteria were randomised to an 8-week treatment period.
During this period patients stopped their regular inhaled
glucocorticosteroids and started using the respective study
treatments. Patients were trained to use their study medjcation
with a large-volume spacer. Five breaths at tidal volume
directly followed one actuation of study medication
administered into the spacer. Care of the spacer was similar for
the two groups. A new diary was supplied to patients at
randomisation to continue entries as before and in addition to
N:21
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Study design and plan
Patients were symptomatic, fulfilling at least one of the
following criteria before randomisation: (z) use of more than 6
inhalations of a short-acting ~2-agonistduring the last 7 days of
the run-in; (iz) diurnal variation in morning peak expiratory
flow (mPEF) > 10% on at least 3 days during 7 days of run-in;
and (iii) nocturnal awakening at least 2 out of 14 nights of the
run-in. Forced expiratory volume in 1 second (FEV]) was
required to be more than 50% of predicted normal. 0 asthma
exacerbation or clinically relevant respiratory infection was
present during the 4 weeks before study entry. All patients
were treated with stable doses of inhaled glucocorticosteroids
for at least 8 weeks before enrolment, as shown in Table IT.
Systemic corticosteroids were not used for 8 weeks before visit 1.
Long-acting inhaled or oral ~-agonists, theophylline,
ipratropium bromide and long-acting antihistamines were
withdrawn before visit 1 according to accepted washout times.
Nasal steroids were allowed at stable doses during the study.
No concurrent diseases likely to affect the study were present
in any of our patients. The patients were competent in using
the inhaler and spacer devices. Approval for the study was
obtained from the SteUenbosch University and Tygerberg
Hospital Ethics Committee and all patients signed informed
consent.
A double-blind randomised parallel-group study was
performed with a 2-week run-in followed by an 8-week
treatment period. Patients were randomised to either group 1
(Becotide, GlaxoWellcome, 400 pg twice daily) or group 2
(Beclate, Cipla Medpro, 400 pg twice daily), using a table of
random numbers. IdenticallabeUing of the canisters ensured
blinding. Study medication was delivered by metered dose
inhalers and administered through large-volume spacers (Cipla
Medpro).
Primary variables were changes from baseline to end of
treatment in: (i) mPEF recorded daily in patient diaries;
(iz) FEV1 % of predicted normal measured at clinic visits; and
(iii) histamine concentration provoking a 20% reduction in
FEV1 (histamine PC20). Secondary clinical variables were
•
January 2001, Vo!. 91, o. 1 SAMJ
ORIGINAL ARTICLES
record the use of twice-daily study medication. A value
indicating a 30% drop in average mPEF as measured during
the run-in period was entered on the diary cover. This served
as an indicator of deterioration in asthma control during the
treatment period. A safety visit and compliance check were
performed 2 weeks after randomisation. All the visits were
scheduled for the same time in the morning.
Compliance was estimated from entries on use of study
medication in patient diaries. Patients were discontinued for
deterioration in asthma control, as well as for protocol violation
and non-compliance.
Clinical assessments and lung function
Demographic details were recorded for all patients and
relevant medical history, including smoking history,
concomitant disease and recent airway infections as well as
prescribed medication during the past 4 weeks were
documented. A physical examination was done on all patients
and a skin prick test was performed using a validated
method.!' Each individual kept a diary for his/her own
recordings. Peak flow measurements were done in the
standing position and patients were requested to record the
highest of three consecutive blows. Patients were asked to
avoid using rescue medication during the 6 hours before PEF
measurements and clinic visits. Graded asthma symptoms,
intake of rescue medication, nocturnal awakening and use of
study medication were recorded.
Pulmonary function data were measured at body
temperature and saturated atmospheric pressure using a
spirometer that was calibrated daily. Lung function testing was
done after patients had rested for 20 minutes. FEV] was
measured and the calculation of FEY]% of predicted was based
on reference values as suggested by the European Respiratory
Society. IS The highest measured value from three acceptable
efforts was chosen and recorded on each occasion.
Histamine provocation tests were done on patients with
FEY] > 60% of predicted normal at randomisation and at the
end of the treatment period. This was done using a validated
method.'· Baseline FEYl was measured 60 seconds post
inhalation of normal saline. The patient then inhaled histamine
for 2 minutes at a concentration of 0.03 mg/m!. This
Concentration was doubled at 5-minute intervals, until the FEY]
dropped by 20% from the baseline FEY]. The histamine PCzo
was determined in mg/m! by interpolating the last 2 points of
the dose response curve on a logarithmic scale.
Data management and statistical analysis
Data were entered on a spreadsheet in a blind mode and edited
against the source data. The treatment groups were coded for
analysis. All decisions regarding the availabillty of the aata
and the analyses were taken before breaking of the code.
Graphs of the rnPEF were generated for each patient to assess
the Within-patient and period variability. Intention-to-treat
analysis was performed. To investigate the effect of outliers in
the data, an analysis based on median values was compared
with an analysis based on mean values. These were similar,
therefore analyses based on mearJS were used in all subsequent
analyses. The Schuirmarm two one-sided tests procedure was
used for equivalence testing: Ho: Uz - Ul ::; -61, or Uz - Ul ~ ~;
Ha: -6l < Uz - Ul < -62.20 Ninety-five per cent confidence intervals
(CIs) for the differences in means, from baseline to end of
treatment, were calculated and clinical limits were set for the
primary variables (20% for rnPEF and FEV1 and two doubling
doses for histamine PCzo). Two approaches were used. Firstly,
a summary value was calculated for each patient for the
variables concerned. This was the mean of the last 7 days of
run-in and the last 14 days of the treatment period. The mean
difference from run-in to end of treatment was calculated with
its Cl. Secondly, an analysis of individual values in each
period was done for rnPEF using the linear mixed-effect model.
The period effect was investigated and adjusted for sex and age
as well as the time-effect in each patient. The result of the more
complex linear mixed-effect model for rnPEF was comparable
to the analysis using the difference in mean values. The
difference in mean values was therefore used in subsequent
analysiS.
RESULTS
Thirty-eight patients were entered in the run-in period, two of
whom did not comply with randomisation criteria. Thirty-six
patients were randomised to the respective treatment groups
and 32 evaluable patients completed the study. Randomisation
resulted in two comparable groups (Tables I and IIl). Moderate-
to-severe asthmatics were included in the study, as suggested
by significant levels of bronchial hyper-responsiveness (Table
Ill). The transition from run-in to treatment periods was
LII1.femarkable and there was no significant period effect. The
sample size was sufficient to differentiate the groups for mPEF,
although this was within 10% of baseline and within the set
clinical limits (Fig. 1, Table IIl).
The differences in effect for the primary variables, end of
treatment compared with baseline, were 5.6l/min (Cl -16.4 -
27.6) and -22.3l/min (Cl -9.0 - -35.6) for mPEF; ·-2.9%
(Cl -11.0 - 5.2) and 0.2% (--4.8 - 5.2) for FEY] % of predicted
normal; and -D.04 mg/m! (Cl -D.15 - 0.06) and 0.02 mg/m! (Cl
-D.37 - 0.4) for histamine PCzo ' for treatment groups 1 and 2
respectively (Table Ill, Fig. 1).
The decrease in rnPEF in group 2 was not accompanied by
an increase in bronchial hyperreactivity at the end of the
treatment period. The mean differences from baseline to end of
treatment, with 95% CIs, were within the clinical limits set for
therapeutic equivalence for all the primary variables
(Fig. 1). The null hypothesis of inequality as suggested by
Schuirmann was therefore rejected and the alternative
hypothesis of equality accepted.
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Table IlL DiHerence in effect - end of treatment compared with baseline
Difference in treatment effect
Baseline (P1) End of treatment (p:z) (P2 - PI)
Mean (SEM) Mean(SEM) Mean 95%0
10 Efficacy variables
MPEFl/min
Group 1 (N =16) 385.0 (14.1) 390.6 (14.4) 5.6 -16.4-27.6
Group 2 (N =16) 384.7(192) 362.4 (20.1) -22.3 -35.6 - 9.0
FEYI % predicted
Group 1 (N =16) 73.6 (3.0) 70.7 (4.1) -29 -11 - 5.2
Group 2 (N =16) 66.6 (2.5) 68.6 (3.3) 0.2 4.8 -5.2
PC20 mg/ml
Group 1 (N =15) 0.12 (0.02) 0.08 (0.04) -0.04 -0.15 - 0.06
Group 2 (N =12) 0.09 (0.16) 0.30 (0.11) 0.02 --0.38 - 0.4
20 Efficacy variables
I\-agonist use puffs/d
Group 1 (N =16) 3.36 (0.5) 3.05 (0.45) -0.31 -1.49 - 0.87
Group 2 (N =16) 2.86 (0.4) 3.23 (0.4) 0.37; -0.54 - 1.28
Symptom score/d
Group 1 (N =16) 1.3 (0.2) 1.3 (0.17) 0.0 -0.6 - 0.6
Group 2 (N =16) 1.79 (02) 227 (0.2) 0.48 -0.018 - 0.97
Nocturnal awakening
/10 days
Group 1 (N =16) 2 (0.8) 3 (1.1) 1 -1.5 - 3.5
Group 2 (N =16) 2 (0.9) 2 (0.7) 0 -2.0 - 2.0
SEM = sGndan:I error of mean.
III
The dilierence in effect for the clinical variables was non-
conclusive, as demonstrated in Fig. 1. No serious adverse
events were reported during the study. Six patients, 3 in each
group, experienced deterioration in asthma control but none of
them required hospitalisation. Common cold symptoms were
reported in 5 patients in group 1 and 7 in group 2. (The trial
was performed during the winter months.) One patient in
group 2 developed pharyngeal thrush. Both formulations were
well tolerated by all patients.
DISCUSSION
We have examined the therapeutic equivalence of an innovator
and a generic formulation of BDP in moderate-to-severe
asthmatic aduits using efficacy variables proposed in a
consensus statement by the British Association for Lung
Research in 1994.12 Results of our study demonstrated that the
mean differences with 95% CIs of such variables were
contained within the limits set for equivalence.'"
Expiry of patent periods for innovator formulations and
changes in governmental regulations provides the opportunity
for generic or interchangeable multisource products to enter
the marketplace at a lower cost.lo,n The question is whether
these formulations are therapeutically equivalent to their
innovator counterparts. Determination of bio-equivalence for
inhaled products remains problematic. 'O,l3 Four principal
methodologies are currently available to compare equivalence
of different inhaler devices. llie first of these methodologies is
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an in vitro procedure, which is based on the inertial behaviour
of particle clouds emitted by inhalers. The 'respirable fraction',
a standard means of evaluating inhaled products, is based on
the percentage of drug contained in particles less than 5 llIll in
diameter. This measure of equivalence, favoured by regulatory
authorities, may not correlate with efficacy in patients.10
Three in vivo methods are available to assess equivalence,
namely:
1. Radio-aerosol drug deposition study (gamma
scintigraphy), which assesses the pattern of delivery to the
patient and quantifies distribution within the lungs.
2. Pharmacokinetic studies, which are generally of limited
value in the study of inhaled medication. Drugs administered
by inhalation differ from those administered by ingestion in
several ways. Administration of inhaled drugs is intended for
local rather than systemic deposition. This creates difficulty in
the testing of inhaled products using bio-availability criteria
because blood concentrations are usually very low,
Furthermore, the inhaled drug in the blood is not necessarily
equivalent to the dose deposited in the lungs in terms of
amount or efficacy.
3. Comparative pharmacodynamic and clinical efficacy
studies. These studies, including our study, are ultimately the
most reliable measure of effectiveness for any medication and
constitute the preferred assessment in comparisons of the
performance of dilierent medications and inhalation device
combinations.lO,l3
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LUNG FUNCTION VARIABLES
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Fig. 1. Mean difference in effect, end of treatment compared with baseline, with 95% confidence intervals.
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